{"id":"W4402704826","doi":"10.1016/j.annonc.2024.08.1799","title":"1706P Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country phase I/IIa expansion cohort","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Clear cell renal cell carcinoma; Antibody; Oncology; Center (category theory); Cancer research; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107208,0.0003728093,0.0006409501,0.0001873419,0.0001868615,0.0006852464,0.0003492627,0.0003675325,0.001538989],"category_scores_gemma":[0.0006887492,0.0002103894,0.0006873076,0.000367427,0.0003834316,0.000651258,0.0002792038,0.001131328,0.0005299895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005741453,"about_ca_system_score_gemma":0.0005237912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009138867,"about_ca_topic_score_gemma":0.001828154,"domain_scores_codex":[0.9996423,0.0001493332,0.00001525167,0.00007713107,0.00005718109,0.00005877915],"domain_scores_gemma":[0.9996544,0.0000721468,0.00008751612,0.00004491294,0.00003668618,0.0001043017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2565106,0.01065236,0.322541,0.0006289451,0.004521414,0.0005291501,0.0005605887,0.01142628,0.08556248,0.0004787347,0.01194311,0.2946453],"study_design_scores_gemma":[0.04857962,0.1732603,0.7287563,0.00009605776,0.004020412,0.002152189,0.0004621778,0.006252947,0.01914028,0.0006311943,0.01651938,0.000129189],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964784,0.0008818799,0.0001353082,0.0001462873,0.00001346381,0.0000564871,0.001310412,0.00001962507,0.0009583138],"genre_scores_gemma":[0.9956048,0.0004985743,0.0002589203,0.0002148249,0.00002219313,0.00006196593,0.002552066,0.00001472303,0.0007720111],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001538989,"threshold_uncertainty_score":0.005669773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0383632720361082,"score_gpt":0.3446306236885068,"score_spread":0.3062673516523986,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}